Al-Ola A Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared a post on X:
“That moment you see a rapid Talquetamab response in a heavily pre-treated, quad-refractory myeloma patient (PI/IMiD/CD38 mAb/BDT). The speed of response says it all.”
More posts featuring Al-Ola A Abdallah.